Alenezi Wejdan M, Fierheller Caitlin T, Serruya Corinne, Revil Timothée, Oros Kathleen K, Subramanian Deepak N, Bruce Jeffrey, Spiegelman Dan, Pugh Trevor, Campbell Ian G, Mes-Masson Anne-Marie, Provencher Diane, Foulkes William D, Haffaf Zaki El, Rouleau Guy, Bouchard Luigi, Greenwood Celia M T, Ragoussis Jiannis, Tonin Patricia N
Department of Human Genetics, McGill University, Montreal, QC, Canada.
Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, QC, Canada.
Front Oncol. 2023 Mar 8;13:1111191. doi: 10.3389/fonc.2023.1111191. eCollection 2023.
Not all familial ovarian cancer (OC) cases are explained by pathogenic germline variants in known risk genes. A candidate gene approach involving DNA repair pathway genes was applied to identify rare recurring pathogenic variants in familial OC cases not associated with known OC risk genes from a population exhibiting genetic drift. Whole exome sequencing (WES) data of 15 OC cases from 13 families tested negative for pathogenic variants in known OC risk genes were investigated for candidate variants in 468 DNA repair pathway genes. Filtering and prioritization criteria were applied to WES data to select top candidates for further analyses. Candidates were genotyped in ancestry defined study groups of 214 familial and 998 sporadic OC or breast cancer (BC) cases and 1025 population-matched controls and screened for additional carriers in 605 population-matched OC cases. The candidate genes were also analyzed in WES data from 937 familial or sporadic OC cases of diverse ancestries. Top candidate variants in , , and were identified in 5/13 (39%) OC families. Collectively, candidate variants were identified in 7/435 (1.6%) sporadic OC cases and 1/566 (0.2%) sporadic BC cases versus 1/1025 (0.1%) controls. Additional carriers were identified in 6/605 (0.9%) OC cases. Tumour DNA from and variant carriers exhibited loss of the wild-type allele. Carriers of various candidate variants in these genes were identified in 31/937 (3.3%) OC cases of diverse ancestries versus 0-0.004% in cancer-free controls. The strategy of applying a candidate gene approach in a population exhibiting genetic drift identified new candidate OC predisposition variants in DNA repair pathway genes.
并非所有家族性卵巢癌(OC)病例都可由已知风险基因中的致病种系变异来解释。我们采用了一种涉及DNA修复通路基因的候选基因方法,以在一个存在遗传漂变的人群中,识别出与已知OC风险基因无关的家族性OC病例中罕见的复发性致病变异。对13个家族的15例OC病例的全外显子测序(WES)数据进行研究,这些病例在已知OC风险基因中检测出致病变异为阴性,以寻找468个DNA修复通路基因中的候选变异。将筛选和优先级标准应用于WES数据,以选择顶级候选者进行进一步分析。在214例家族性和998例散发性OC或乳腺癌(BC)病例以及1025例人群匹配对照的祖先定义研究组中对候选者进行基因分型,并在605例人群匹配的OC病例中筛选其他携带者。还对来自937例不同祖先的家族性或散发性OC病例的WES数据中的候选基因进行了分析。在5/13(39%)的OC家族中鉴定出了 、 、 和 中的顶级候选变异。总体而言,在7/435(1.6%)的散发性OC病例和1/566(0.2%)的散发性BC病例中鉴定出候选变异,而对照中为1/1025(0.1%)。在6/605(0.9%)的OC病例中鉴定出其他携带者。来自 和 变异携带者的肿瘤DNA显示野生型等位基因缺失。在31/937(3.3%)的不同祖先的OC病例中鉴定出这些基因中各种候选变异的携带者,而在无癌对照中为0 - 0.004%。在一个存在遗传漂变的人群中应用候选基因方法的策略,在DNA修复通路基因中鉴定出了新的OC易感性候选变异。